Verastem Oncology (VSTM) has officially commenced the global Phase 1/2 clinical trial (TARGET-D 101, NCT07020221) of VS-7375 (Chinese code name GFH375), a KRAS G12D inhibitor acquired from GenFleet Therapeutics. This marks the company's entry into the next-generation targeted oncology market. VS-7375 is designed as an innovative dual ON/OFF inhibitor, targeting both the active (ON, GTP-bound) and inactive (OFF, GDP-bound) states of cancer cells. Unlike existing approved KRAS G12C inhibitors like Sotorasib or Adagrasib, which only target the OFF state and are prone to resistance, VS-7375 aims to inhibit both states, potentially leading to more potent and sustained tumor suppression. This is particularly significant for patients with KRAS G12D-mutated solid tumors, such as pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC), where treatment options are extremely limited, and it has garnered considerable attention from the scientific and investment communities.

The U.S. Food and Drug Administration (FDA) recently designated VS-7375 as a Fast Track drug for the treatment of KRAS G12D-mutated metastatic pancreatic cancer and non-small cell lung cancer, officially recognizing its innovative nature and urgent need. As a result, Verastem plans to evaluate both monotherapy and combination therapy (e.g., with Cetuximab, an EGFR-targeted therapy for colorectal cancer) in this Phase 1/2 trial to maximize treatment efficacy. The early-stage evaluation of various combination possibilities is a strategic approach to block cancer cell bypass pathways within the complex tumor microenvironment and improve treatment response rates. With support from the FDA's fast-track development program, the clinical results could significantly accelerate the progression to later-stage trials and early commercialization.

This clinical trial initiation represents a key development milestone following Verastem's decision to exercise its early option to acquire VS-7375 from GenFleet in January 2025. The two companies entered into a co-development agreement in August 2023, totaling $625.5 million (USD), with Verastem making an upfront payment and research support of $11.5 million (USD) for the first program, VS-7375. Verastem's decision to exercise the exclusive license option ahead of schedule was driven by the promising pharmacokinetic properties and strong initial anti-tumor efficacy data demonstrated in the Phase 1 trial conducted in China. This is considered a prime example of a strategic partnership between biotech companies, where risks are shared while securing promising assets early on.

The global KRAS G12D inhibitor market is projected to grow rapidly, from approximately $3.8 billion (USD) in 2025 to $18.5 billion (USD) in 2034, with a compound annual growth rate of 19.2%. Currently, Mirati's MRTX1133, a non-covalent inhibitor acquired by Bristol Myers Squibb (BMS), was a leading candidate, but its progress has slowed due to challenges in the Phase 1 trial. Meanwhile, Astellas Pharma's PROTAC, ASP3082 (cetidegrasib), has entered Phase 3 trials and is emerging as a strong competitor. In this competitive landscape with diverse modalities, Verastem aims to establish a differentiated market position by leveraging the advantages of its small-molecule dual inhibition mechanism and fast-track development.